Search

Your search keyword '"Slapikas, Rimvydas"' showing total 93 results

Search Constraints

Start Over You searched for: Author "Slapikas, Rimvydas" Remove constraint Author: "Slapikas, Rimvydas"
93 results on '"Slapikas, Rimvydas"'

Search Results

1. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

2. Trends in cardiovascular risk factor prevalence among Lithuanian middle-aged adults between 2009 and 2018

3. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

4. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk

5. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

6. Dobutamine-stress echocardiography speckle-tracking imaging in the assessment of hemodynamic significance of coronary artery stenosis in patients with moderate and high probability of coronary artery disease

9. EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT)

11. Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” [Atherosclerosis 290 (2019) 140–205]

12. Erratum to “2019 ESC/EAS guidelines for the management of dyslipidemias: Lipid modification to reduce cardiovascular risk” [Atherosclerosis 290 (2019) 140–205]

13. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, GALACTIC‐HF: baseline characteristics and comparison with contemporary clinical trials

14. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

15. European society of cardiology

16. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

17. Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial

18. Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events The ODYSSEY OUTCOMES Trial

19. Effects of alirocumab on types of myocardial infarction : insights from the ODYSSEY OUTCOMES trial

20. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

21. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

22. The chronic ischaemic cardiovascular disease ESC Pilot Registry: Results of the six-month follow-up

24. Early and late diastolic strain rate vs global longitudinal strain at rest and during dobutamine stress for the assessment of significant coronary artery stenosis in patients with a moderate and high probability of coronary artery disease

26. EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT)

28. The fear of dying and occurrence of posttraumatic stress symptoms after an acute coronary syndrome: A prospective observational study.

35. Prognostic value of myocardial perfusion abnormalities for long-term prognosis in patients after coronary artery bypass grafting.

38. The risk of cardiovascular death following the first acute ischaemic syndrome: experience in Kaunas between 1997 and 2001

39. Informative value of clinical markers for the risk of cardiovascular death in postinfarction chronic heart failure

40. Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

41. The fear of dying and occurrence of posttraumatic stress symptoms after an acute coronary syndrome: A prospective observational study.

42. Prevalence of high-risk profile in middle-aged subjects with arterial hypertension: a nationwide survey.

43. High-risk profile in a region with extremely elevated cardiovascular mortality.

44. Incidentally diagnosed malignant coronary artery anomaly: a clinical case.

45. Effectiveness of telemedicine and distance learning applications for patients with chronic heart failure. A protocol for prospective parallel group non-randomised open label study.

46. The impact of myocardial revascularization after acute coronary syndromes on one-year cardiovascular mortality.

47. [Associations between acute heart failure and cardiovascular outcomes].

48. [Diagnostic value of multislice computed tomography coronary angiography in patients with left bundle branch block].

49. Image quality of 16-slice computed tomography coronary angiography in patients with complete left bundle branch block.

50. Implementation of international transtelephonic ECG platform for patients with ischemic heart disease.

Catalog

Books, media, physical & digital resources